Fecal Incontinence
Fecal Incontinence Market

Fecal Incontinence

Fecal Incontinence (FI) is the involuntary passage of fecal matter through the anus or the inability to control the discharge of bowel contents. Fecal incontinence has many causes, including diarrhea, constipation, muscle damage or weakness, nerve damage, loss of stretch in the rectum, childbirth by vaginal delivery, hemorrhoids and rectal prolapse, rectocele, and inactivity.


Fecal Incontinence Epidemiology Segmentation


  • Total Prevalence of Fecal Incontinence
  • Gender-specific Fecal Incontinence
  • Prevalent Cases of Fecal Incontinence based on Risk Factors
  • Prevalence of Fecal Incontinence based on the frequency


Fecal Incontinence Epidemiological Insights Observed in 2020

The total Fecal Incontinence prevalent cases were found to be approx 11 million in the 7MM countries.


Fecal Incontinence Market Insight

The Fecal Incontinence market size was found to be USD 1,880 million in the 7MM in 2020.


Fecal Incontinence Market Drivers


  • The rise in prevalence
  • Escalation in diagnostic opportunities


Fecal Incontinence Market Barriers


  • Unreported diseases
  • Absence of effective treatment


Fecal Incontinence Emerging Drugs


The emerging drugs in the Fecal Incontinence market are


  • Autologous Muscle-Derived Cells
  • RDD-0315, and several others


Key Fecal Incontinence Companies


The key companies working in the Fecal Incontinence market are


  • Cook MyoSite
  • 9 Meters Biopharma, and several others